Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de la Facultad de Medicina
Print version ISSN 0120-0011
Abstract
ESCOBAR, Hellmann Adrián et al. Pharmacological treatment of patent ductus arteriosus in premature infants. rev.fac.med. [online]. 2019, vol.67, n.2, pp.333-339. ISSN 0120-0011. https://doi.org/10.15446/revfacmed.v67n2.64146.
Introduction:
Pharmacological management ofpatent ductus arteriosus (PDA) usually includes non-selective inhibitors of the enzyme cyclooxygenase, especially indomethacin and ibuprofen. Recently, acetaminophen has also been suggested as a therapeutic alternative.
Objective:
To conduct a narrative review of the literature on pharmacological management of PDA.
Materials and methods:
Structured literature search conducted on the ProQuest, EBSCO, ScienceDirect, PubMed, LILACS, Embase, Trip Database, SciELO and Cochrane Library databases, with the terms "Ductus Arteriosus, patentAND therapeutics"; "Ductus Arteriosus, patent AND indometacin"; "Ductus Arteriosus, Patent AND ibuprofen", and "Ductus Arteriosus, patent AND acetaminophen", and their equivalents in Spanish.
Results:
69 articles had relevant information to carry out the present review.
Conclusions:
In premature infants, the mainstay of pharmacological treatment for PDA continues to be non-selective cyclooxygenase inhibitors, indomethacin and ibuprofen, all with similar safety and efficacy profiles. The available evidence suggests that acetaminophen may be a useful alternative for management, but it is insufficient to make definitive recommendations regarding the efficacy and safety of this drug.
Keywords : Ductus Arteriosus, Patent; Therapeutics; Indomethacin; Ibuprofen; Acetaminophen; Anti-Inflammatory Agents; Non-Steroidal (MeSH).